NEW YORK — Aidoc announced on Tuesday that it raised $150 million in a new funding round. The clinical artificial intelligence company secured the capital from three primary investors, including Goldman Sachs, SoftBank Vision Fund 2, and NVentures. The cash injection follows the firm's efforts to scale its medical diagnostic software across global healthcare markets during 2024.
The company confirmed that the $150 million will be used to enhance its existing AI platform. Aidoc provides software that assists radiologists in diagnosing medical conditions across various hospital systems. Management did not provide a specific date for when these new hospital contracts will be finalized by the end of 2025.
Aidoc leadership is currently evaluating the timeline for a potential initial public offering. The company said in a statement that it is weighing the prospects of going public to provide further resources for its operations. While no specific IPO date was set, the firm noted that the $150 million provides the necessary capital to meet public market scrutiny requirements.
Goldman Sachs and SoftBank Vision Fund 2 joined the round to support the firm's diagnostic technology. These investors have backed the company as it seeks to increase its presence in the healthcare sector. The firm currently serves hospitals that rely on its tools to improve diagnostic accuracy for thousands of patients every single day.
The company did not disclose the specific valuation assigned to the business during this $150 million funding event. Aidoc remains focused on its goal of broadening hospital adoption rates by the end of 2025. The firm did not respond to a request for comment regarding the exact number of employees it plans to hire with the new capital.
